The role of magnesium supplementation in cisplatin-induced nephrotoxicity in a rat model: No nephroprotectant effect

International Journal of Preventive Medicine

Volumn 3, Issue 9, 2012, Pages 637-643

  Ashrafi, Farzaneh ^a   Haghshenas, Sara ^a   Nematbakhsh, Mehdi ^a,b   Nasri, Hamid ^a,b   Talebi, Ardeshir ^a   Eshraghi Jazi, Fatemeh ^a   Pezeshki, Zahra ^a   Safari, Tahereh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cisplatin; Magnesium; Nephrotoxicity; Rat

Indexed keywords

CISPLATIN; CREATININE; MAGNESIUM; MAGNESIUM SULFATE; NITRITE; NITROGEN; SODIUM CHLORIDE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY MASS; KIDNEY PARENCHYMA; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RENAL PROTECTION; TESTIS WEIGHT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84867054660     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lee YC, Saijo N, Sasaki Y, Takahashi H, Sakurai M, Ishihara J, et al. Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay. Jpn J Cancer Res 1986;77:312-8.
2. Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 1985;780:167-80.
3. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 2006;17:207-15.
4. Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 2001;57:393-402.
5. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 1996;39:131-7.
6. Donadio C, Lucchesi A, Gadducci A. Minimization of cisplatin nephrotoxicity in high-risk patients. Nephron 1996;73:325-6.
7. Santos NA, Catao CS, Martins NM, Curti C, BianchiML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007;81:495-504.
8. Sayed-Ahmed MM, Eissa MA, Kenawy SA, MostafaN, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004;50:162-70.
9. Gupta V, Singh SM. Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma. Anticancer Drugs 2008;19:583-92.
10. Babu DM, Satish CS, Shah AP, Shivakumar HG. Preparation and characterization of poly(2-hydroxyethyl methacrylateco-methyl methacrylate) hydrogels for sustained delivery of antitumor drug. Curr Drug Deliv 2011 [In press].
11. Verma AK, Sachin K. Novel hydrophilic drug polymer nano-conjugates of Cisplatin showing long blood retention profile: Its release kinetics, cellular uptake and bio-distribution. Curr Drug Deliv 2008;5:120-6.
12. Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv 2011;8:59-69.
13. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of Cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003;103:645-62.
14. N'Soukpoe-Kossi CN, Descoteaux C, Asselin E, Tajmir-Riahi HA, Berube G. DNA interaction with novel antitumor estradiol-platinum(II) hybrid molecule: A comparative study with cisplatin drug. DNA Cell Biol 2008;27:101-7.
15. Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009;8:2266-75.
16. Lajer H, Kristensen M, Hansen HH, Nielsen S, FrokiaerJ, Ostergaard LF, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005;56:535-42.
17. Goren MP. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 2003;41:186-9.
18. Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 2006;8:710-8.
19. Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 2005;55:231-6.
20. Martin M, Diaz-Rubio E, Casado A, Lopez Vega JM, Sastre J, Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 1992;15:348-51.
21. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, Szczylik C. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. Eur J Cancer 2008;44:2608-14.
22. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997;28:35-40.
23. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 1985;28:914-21.
24. Virag V, May Z, Kocsis I, Blazovics A, Szentmihalyi K. Effects of magnesium supplementation on calcium and magnesium levels, and redox homeostasis in normolipidemic and food-induced hyperlipidemic rats. Orv Hetil 2011;152:1075-81.
25. Ammer U, Natochin Y, David C, Rumrich G, Ullrich KJ. Cisplatin nephrotoxicity: Site of functional disturbance and correlation to loss of body weight. Ren Physiol Biochem 1993;16:131-45.
26. Ohno T, Kato S, Wakatsuki M, Noda SE, Murakami C, Nakamura M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: Comparison with radiation therapy alone. Gynecol Oncol 2006;103:94-9.
27. Ikarashi N, Ushiki T, Mochizuki T, Toda T, KudoT, Baba K, et al. Effects of magnesium sulphate administration on aquaporin 3 in rat gastrointestinal tract. Biol Pharm Bull 2011;34:238-42.
28. Hemmings FJ, Edbury SM, Davie RJ, Birch NJ. Magnesium and lithium antagonism of carbachol-and electrically-induced smooth muscle contractions in the rat gastrointestinal tract. Magnes Res 1994;7:179-86.
29. Hemmings FJ, Rai J, Padgham C, Birch NJ. Magnesium inhibition of carbachol-induced contractions of the rat uterus and gastrointestinal tract: Ex vivo effect of long term streptozotocin-induced diabetes. Magnes Res 1993;6:343-8.
30. Srivastava RC, Farookh A, Ahmad N, Misra M, Hasan SK, Husain MM. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals 1996;9:139-42.
31. Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: Role of nitric oxide. Basic Clin Pharmacol Toxicol 2005;97:91-7.
32. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, et al. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1997;1:88-94.
33. Turchi JJ. Nitric oxide and cisplatin resistance: NO easy answers. Proc Natl Acad Sci U S A 2006;103:4337-8.
34. Rock E, Astier C, Lab C, Malpuech C, Nowacki W, Gueux E, et al. Magnesium deficiency in rats induces a rise in plasma nitric oxide. Magnes Res 1995;8:237-42.
35. Kohn S, Fradis M, Podoshin L, Ben-David J, Zidan J, Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997;21:289-99.
36. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36.
37. Filipski KK, Mathijssen RH, Mikkelsen TS, SchinkelAH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
38. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 2009;13:578-84.
39. Yuan J, Zhou J, Chen BC, Zhang X, Zhou HM, Du DF, et al. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 2005;37:1892-5.
40. Holzmacher R, Kendziorski C, Michael Hofman R, Jaffery J, Becker B, Djamali A. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 2005;20:1456-62.
41. Asai T, Nakatani T, Yamanaka S, Tamada S, KishimotoT, Tashiro K, et al. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 2002;74:784-91.
42. Pere AK, Lindgren L, Tuomainen P, Krogerus L, RauhalaP, Laakso J, et al. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int 2000;58:2462-72.
43. Mervaala EM, Pere AK, Lindgren L, Laakso J, Teravainen TL, Karjala K, et al. Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997;29:822-7.
44. Rankin LI, Krous H, Fryer AW, Whang R. Enhancement of gentamicin nephrotoxicity by magnesium depletion in the rat. Miner Electrolyte Metab 1984;10:199-203.
45. Mochizuki M, Akagi K, Inoue K, Shimamura K. A single dose toxicity study of magnesium sulfate in rats and dogs. J Toxicol Sci 1998;23(Suppl 1):31-5.